Free · No account

Create your own personal news briefing

A daily PDF of the news that moves your tickers — summaries and market impact, delivered an hour before the open.

Zacks Investment Research

29 Jun 2026, 18:46 UTC · 1h ago

Is HRMY Stock Worth Buying With Neutral Signals and Cheap Valuation?

NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.

What the story claims

4 claims · each scored for market impact

What matters in this story

1
Harmony Biosciences (HRMY) reported quarterly earnings of $0.55 per share and net product revenues of $215.4 million, both missing Zacks Consensus Estimates. — Missing both top and bottom line expectations typically triggers negative short-term price action.
-0.40
2
Harmony Biosciences reiterated its 2026 Wakix net revenue guidance of $1.0 billion to $1.04 billion. — Reaffirming guidance provides a floor for valuation and signals management's confidence in the primary revenue driver.
+0.30
3
Harmony Biosciences ended Q1 2026 with $870.5 million in cash, cash equivalents, and investments. — A strong cash position reduces financial risk and provides a buffer for pipeline development.
+0.20
4